Plasma IL-8 and IL-6 levels can be used to define a group with low risk of septicaemia among cancer patients with fever and neutropenia.
about
Performance of Interleukin-6 and Interleukin-8 serum levels in pediatric oncology patients with neutropenia and fever for the assessment of low-risk.Risk factors for negative blood cultures in adult medical inpatients--a retrospective analysis.Role of interleukin-6 in mortality from and physiologic response to sepsisCirculating inflammatory mediators in patients with fever: predicting bloodstream infection.Systematic review and meta-analysis of the value of initial biomarkers in predicting adverse outcome in febrile neutropenic episodes in children and young people with cancer.Prediction of outcome in cancer patients with febrile neutropenia: a prospective validation of the Multinational Association for Supportive Care in Cancer risk index in a Chinese population and comparison with the Talcott model and artificial neuralThe diagnostic value of CRP, IL-8, PCT, and sTREM-1 in the detection of bacterial infections in pediatric oncology patients with febrile neutropenia.Plasma levels of procalcitonin and eight additional inflammatory molecules in febrile neutropenic patients.The evolution towards ambulatory and day-case management of febrile neutropenia.Selected inflammatory markers in the diagnosis and monitoring of infections in children treated for hematological malignancies.Endothelial cells are main producers of interleukin 8 through Toll-like receptor 2 and 4 signaling during bacterial infection in leukopenic cancer patients.Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO).Value of lipopolysaccharide binding protein as diagnostic marker of infection in adult cancer patients with febrile neutropenia: comparison with C-reactive protein, procalcitonin, and interleukin 6.Diagnostic Accuracy of Interleukin-6, Interleukin-8, and Interleukin-10 for Predicting Bacteremia in Children with Febrile Neutropenia.Bacteraemia coincides with low citrulline concentrations after high-dose melphalan in autologous HSCT recipients.The role of oral mucositis on the systemic inflammation parameter IL-8 in febrile neutropenic cancer patients.Circulating inflammatory mediators during start of fever in differential diagnosis of gram-negative and gram-positive infections in leukopenic ratsAssessment of systemic inflammation markers to differentiate a stable from a deteriorating clinical course in patients with febrile neutropenia.Identification of children presenting with fever in chemotherapy-induced neutropenia at low risk for severe bacterial infection.Clinical value of serial measurement of serum C-reactive protein level in neutropenic patients.Procalcitonin in paediatric cancer patients: its diagnostic relevance is superior to that of C-reactive protein, interleukin 6, interleukin 8, soluble interleukin 2 receptor and soluble tumour necrosis factor receptor II.Effects of RWJ 67657, a p38 mitogen activated protein kinase (MAPK) inhibitor, on the production of inflammatory mediators by rheumatoid synovial fibroblasts.The mild inflammatory response in febrile neutropenic lymphoma patients with low risk of complications is more pronounced in patients receiving tobramycin once daily compared with three times daily.
P2860
Q33322617-E2E5B8EF-0199-41F6-9B11-9AEE1E3A9921Q33379958-336C126A-3077-4B9D-90ED-06E54C338C35Q33769122-3F22D03F-6F8E-4422-AA7C-75CEDFD2845CQ33999769-825252EC-613A-4AE8-9D20-BE260CE1210BQ34132502-59E6BCE2-D39E-48F4-93CA-B485B0FD6A01Q34623175-E17A40E6-72BF-41CF-8941-CD0B8FEF5A0AQ35195245-6613B169-4207-4DE7-A76D-CE59D21F256EQ35232470-D8B05D24-5C20-44B1-AB68-3430C72A5547Q36573955-718FA7C3-CF7D-4269-9A75-37203EE84E98Q38488118-1A7AA3F3-90F1-4B07-AB32-C684571C2936Q39785740-5F94E4BC-AA56-4539-8AFF-353F9C0D2E84Q40041299-6E355514-B326-44B7-9AC1-82B648BD057FQ40174792-F5476BFF-A563-4725-8419-28F1BF0C55A2Q40349952-C5EC533C-3F2D-4B29-867C-A65DA7CF6B2CQ40415634-54D95C50-80FC-4759-9233-E93DF7EA8E49Q40471257-1718A0FD-3713-4811-88DC-289C6094F33DQ40499199-7975474E-5801-45EC-A2EA-D6C2918E5D3CQ40512637-92158257-2F23-4F06-A37B-181957F4DF12Q40549387-EB1D8A77-5A19-4F58-97C2-4824D44B8ABCQ40602270-FF7212AC-96E3-4E51-B6ED-6704705C6623Q40609219-7D942156-6FD2-4AFD-A6F5-398BD8797617Q41879329-A388FCA3-1D4D-4D83-B71B-F8B822677FFFQ53222325-58D7A731-604C-45C1-A355-82DF14D43C02
P2860
Plasma IL-8 and IL-6 levels can be used to define a group with low risk of septicaemia among cancer patients with fever and neutropenia.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Plasma IL-8 and IL-6 levels ca ...... ts with fever and neutropenia.
@en
type
label
Plasma IL-8 and IL-6 levels ca ...... ts with fever and neutropenia.
@en
prefLabel
Plasma IL-8 and IL-6 levels ca ...... ts with fever and neutropenia.
@en
P2093
P2860
P1476
Plasma IL-8 and IL-6 levels ca ...... ts with fever and neutropenia.
@en
P2093
Swaanenburg JC
Vellenga E
Visser-van Brummen PJ
de Bont ES
P2860
P304
P356
10.1046/J.1365-2141.1999.01707.X
P407
P577
1999-11-01T00:00:00Z